With the end of the year around the corner, the transition period after Brexit is about to come to an end. From 1 January 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) will be the United Kingdom’s standalone medicines and medical devices regulator.
Novel Regeneration Techniques for Large Bone Defects: Launch of EU Research Project SBR
The ten academic and industrial partners collaborating in the new EU research project SBR (Smart Bone Regeneration) aim to improve treatment options for patients with large bone defects.
Regulating medical devices in the event of a no-deal Brexit
Even though there is a fair amount of turmoil regarding Brexit, MHRA is getting ready for a worst-case scenario, a no-deal Brexit.
